Stock Financial Ratios, Dividends, Split History

VOYA / Voya Financial, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price49.11
Volume1,095,800.00
Market Cap ($M)8,138.55
Enterprise Value ($M)11,216.55
Book Value ($M)9,378.00
Book Value / Share55.55
Price / Book0.87
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 184,100,000
Weighted Average Number Of Diluted Shares Outstanding 184,100,000
Common Shares Outstanding 172,003,659
Common Stock Shares Outstanding 172,000,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.20
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.21
Balance Sheet (mrq) ($M)
Assets219,824.00
Liabilities209,415.00
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues8,618,000,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Sales Revenue Net8,046,000,000.00
Revenue Other Financial Services0.00
Revenues Attributableto Noncontrolling Interest0.00
Supplementary Insurance Information Premium Revenue4,748,000,000.00
Net Income-2,792.00
Earnings Per Share Basic-16.25
Earnings Per Share Diluted-16.25
Cash Flow Statement (mra) ($M)
Cash From Operations1,578.00
Cash from Investing-2,428.00
Cash from Financing-2,428.00
Identifiers and Descriptors
CUSIP929089100
Central Index Key (CIK)1535929
Related CUSIPS
092908910 45685E956 929089950 45685E106 929089900
Industry Groups
SIC 6311 - Life Insurance

Split History

Stock splits are used by Voya Financial, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Future Prospects Brighter For Brighthouse Financial

2018-06-27 seekingalpha
Brighthouse Financial was spun-off from Metlife in 2017, representing much of the retail-oriented aspects of the insurance giant. (17-1)

Voya Financial: Bet On This Asset Gatherer

2018-05-20 seekingalpha
Voya Financial (NYSE:VOYA) is breaking out to new highs as it continues to gather assets due to its diversified, unique offerings. In recent quarters, the company has attracted impressive feeable asset growth as it adapts to the market's needs, while offering benchmark-beating results. Its share price is breaking out higher after months of consolidation due to its strong operational results. I am buying stock in the name as its fundamental efficiency is driving investor flows into the company.

ING: An Undervalued Income Play

2018-05-16 seekingalpha
Its dividend yield of 5% is one of the main positive factors of its investment case.

U.S. Stocks Topped Market Performances Last Week

2018-05-15 seekingalpha
The US equity market rebounded last week, posting a gain after two straight weekly declines. The advance topped performances for the major asset classes, based on a set of exchanged-traded products. (7-0)

Voya Financial To Acquire Pen-Cal For Retirement Plan Services

2018-05-11 seekingalpha
Pen-Cal has developed a range of nonqualified deferred compensation benefit plans related consulting services for business owners.

CUSIP: 929089100